Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur to launch preservative-free child flu jab
The FDA has approved the company’s license supplement to market the new formulation of its pediatric influenza vaccine – the only influenza vaccine approved for use in children
The FDA has approved the company’s license supplement to market the new formulation of its pediatric influenza vaccine – the only influenza vaccine approved for use in children
The Spine-health.com poll of 375 back pain patients who were taking Pfizer’s Celebrex, Bextra, or Merck & Co’s Vioxx shows that only 36% are still taking some brand
The development work will be funded under a $5.6 million grant to Biota from the US National Institutes of Health (NIH). Under the agreement, Aerogen will undertake development
The study, which has enrolled the target of 80 patients, is being conducted at 30 sites in the US, Canada and Puerto Rico. It will compare the effects
Virulizin, Lorus’ lead anticancer drug candidate, has demonstrated favorable safety and efficacy in phase I and II clinical trials by stimulating the immune system to attack and destroy
In 2000, troglitazone (GlaxoSmithKline’s Rezulin) was withdrawn from the market due to severe liver toxicity with an unknown mechanism. Troglitazone and other currently marketed drugs, such as rosiglitazone
Intellectual property filings have been made to further strengthen the company’s patent position for its nerve cell targeted protease inhibitor platform technology. More specifically, CepTor has filed to
The primary objective of the phase II clinical trial is to evaluate the safety and tolerability of multiple doses of PRX-00023 in patients with moderate to severe generalized
The two compounds are AL-108, Allon’s lead product candidate currently being evaluated in human clinical trials as a treatment for Alzheimer’s disease, and AL-209, one of Allon’s preclinical-stage
Labopharm is leveraging regulatory approval of the product in France, which will serve as first approval status in a major regulatory jurisdiction, to facilitate the regulatory approval process